However, prospective multi-centre studies will be necessary to confirm the role of NF-L as a biomarker, and how it, together with GDF-15 and FGF-21, can be used most profitably in the investigation of mitochondrial disease. This evidence concerns the gene FGF21 and inborn mitochondrial metabolism disorder.